Research · 2026-11-21
By Alice Kay · Last reviewed 21 Nov 2026
Dihexa peptide in Canada: structure, literature and lot checks
Research-use notice: This article summarizes published scientific literature for educational purposes. It is not medical advice and does not provide dosing, administration or human-use information. Findings described in the literature do not apply to any BlueNex Labs product, which is supplied only for in-vitro laboratory research and not for human or animal use.
Direct answer
Dihexa peptide in Canada is catalogued as a chemically modified analogue of angiotensin IV, also called PNB-0408.
Scope
Cognitive & neuroscience models. Sleep-architecture and neuroendocrine peptides discussed in laboratory literature.
This note does not claim that Alice Kay authored any cited paper.

Direct answer
Dihexa peptide in Canada is catalogued as a chemically modified analogue of angiotensin IV, also called PNB-0408. Its usual research name is N-hexanoic-Tyr-Ile-(6) aminohexanoic amide: a tyrosine–isoleucine core with a hexanoyl cap at one end and a 6-aminohexanoic amide tail at the other.
Scope
Cognitive and neuroscience laboratory models.
This note does not claim that Alice Kay authored any cited paper.
Dihexa is not angiotensin IV. Angiotensin IV is the hexapeptide Val-Tyr-Ile-His-Pro-Phe, written VYIHPF. McCoy and colleagues (2013) named dihexa as N-hexanoic-Tyr-Ile-(6) aminohexanoic amide: the tyrosine and isoleucine from that parent sequence, with non-standard groups at both ends. PubChem lists the formula as C27H44N4O5, the average molecular weight as 504.7 g/mol, the exact mass as 504.331 Da and the CAS number as 1401708-83-5, under CID 129010512.
BlueNex Labs lists Dihexa 10 mg as a lyophilized research-use-only material and ships it within Canada. This guide covers what the published papers establish about the molecule, how later journal notices changed how that record should be read, how dihexa differs from angiotensin IV and from other cognitive-catalogue peptides, and what to check on a lot. It doesn't cover dosing, administration or any use in people or animals.
Dihexa at a glance
| Property | Value | Source |
|---|---|---|
| Research names | Dihexa; PNB-0408 | McCoy et al., 2013; PubChem; Wells et al., 2024 |
| Chemical name | N-hexanoic-Tyr-Ile-(6) aminohexanoic amide; also Hexanoyl-Tyr-Ile-Ahx-NH2 | McCoy et al., 2013; PubChem CID 129010512 |
| Core | L-tyrosyl-L-isoleucine, derived from angiotensin IV (VYIHPF) | McCoy et al., 2013 |
| End groups | N-terminal hexanoyl cap; C-terminal 6-aminohexanoic amide | McCoy et al., 2013; PubChem |
| Molecular formula | C27H44N4O5 | PubChem CID 129010512 |
| Molecular weight | 504.7 g/mol (average); exact mass 504.331 Da | PubChem CID 129010512 |
| CAS number | 1401708-83-5 | PubChem CID 129010512 |
| PubChem | CID 129010512 (L-Tyr, L-Ile form) | PubChem |
These are reference values for the named compound. They aren't lot results. A lot's identity and purity are whatever its own Certificate of Analysis reports.
Structure: a capped dipeptide, not angiotensin IV
Dihexa is not a conventional six-residue peptide. McCoy and colleagues started from angiotensin IV and from a shorter analogue, Nle-Tyr-Ile-His-Pro-Phe (Nle1-AngIV). They report that the activity they were pursuing sat in the N-terminal residues, and that they then modified a tyrosine–isoleucine fragment to reduce metabolic breakdown and raise hydrophobicity.
The resulting structure has three parts:
The core. The residues taken from angiotensin IV are tyrosine and isoleucine, the second and third residues of VYIHPF. PubChem records the L-tyrosyl-L-isoleucine stereochemistry for CID 129010512.
The N-terminal cap. A hexanoyl (N-hexanoic) group replaces a standard amino-acid N-terminus. McCoy and colleagues wrote that they removed the N-terminal amine rather than appending another amino acid, in order to increase hydrophobicity and remove a hydrogen-bonding site.
The tail. A 6-aminohexanoic amide (Ahx-NH2) stands in place of the rest of the angiotensin IV chain. The C-terminus is an amide, not a free carboxylic acid.
A receiving log should not treat “dihexa” and “angiotensin IV” as interchangeable. Dihexa keeps only two of the parent residues and carries non-standard end groups, so its mass cannot be calculated from a six-amino-acid sequence. Identity checks belong against the structure and the expected mass on the lot report. A primer on what peptides are does not make this analogue a standard linear peptide.
What the 2013 paper reported — and the notice attached to it
The first detailed description of dihexa is McCoy et al., 2013, from a Washington State University group, in The Journal of Pharmacology and Experimental Therapeutics. The paper reports that, in rat serum, Nle1-AngIV had a half-life of less than two minutes, while dihexa had a half-life of 335.5 ± 9.5 minutes. It also describes a tracer experiment in which tritiated dihexa, given into the carotid artery with a vascular-space marker, was concentrated in dissected rat brain regions relative to blood. The authors reported that dihexa reversed scopolamine-induced deficits in the Morris water maze in rats, including after oral delivery, and they reported spine-density and aged-rat maze findings.
Those findings have to be read with the journal's later notice. In September 2021 the same journal published a Notice of Concern on the McCoy article. The editors wrote that they wished “to express concern about the article by McCoy et al. of possible image manipulation after reviewing information received from several sources,” that they had shared the concern with the corresponding author and with Washington State University, and that they would await the results of an inquiry. As of the sources opened for this note, the 2013 article had not been retracted, and no later notice resolving the inquiry was found. The chemical name, the design relative to angiotensin IV and the serum-stability comparison remain the usual starting point for identifying the compound. The behavioural and imaging claims in that paper should not be treated as settled.
The retracted HGF/c-Met mechanism paper
A 2014 paper in the same journal, by Benoist and colleagues, argued that the effects described for angiotensin IV–derived peptides, including dihexa, depended on activation of the hepatocyte growth factor (HGF)/c-Met system. That article is no longer part of the reliable record. In April 2025 the journal published a retraction notice (PMID 40312093). The notice states that the article was retracted at the editor's request after a Washington State University investigation found that Figures 1B and 2A/C, and data in a later erratum submission, contained falsified and/or fabricated data, and that Leen H. Kawas and Joseph W. Harding were solely responsible.
Those HGF/c-Met binding and signalling claims should not be cited as established evidence. A catalogue line that still mentions HGF/c-Met laboratory models is a label for how the compound has been discussed, not a substitute for a standing mechanism paper.
Later animal studies do not all point the same way
Two later rodent papers, from groups outside the originating laboratory, do not agree.
Sun, Deng, Fu, Wang, Duan and Zhang (2021), in Brain Sciences, studied six-month-old male APP/PS1 mice, a transgenic Alzheimer-research model, with age-matched wild-type controls. After three months they reported improved Morris water-maze performance, more Nissl-stained neurons, higher synaptophysin, lower IL-1β and TNF-α, higher IL-10, and PI3K/AKT involvement, which the PI3K inhibitor wortmannin reversed. The methods section also contains an unresolved route statement: it says dihexa and wortmannin were “administered intragastrically” and, in the next sentence, that dihexa “was administered intraperitoneally” from six to nine months of age. The authors note that a wortmannin-only control would have been a more complete design. Those results stay in that model and paper. They are not evidence about people or about any commercial vial.
Wells, Azzam, Hiller and Sardinia (2024), in the Journal of Huntington's Disease, tested PNB-0408 (dihexa) in forty male Wistar rats given 3-nitropropionic acid, a mitochondrial toxin used to produce Huntington-like motor and cognitive deficits. Over five weeks, in vehicle, toxin-only and toxin-plus-PNB-0408 groups, the authors reported that the toxin reduced weight gain and impaired spatial learning, memory consolidation and motor function, and that PNB-0408 did not protect against those deficits.
The later literature is therefore mixed: a positive report in one mouse Alzheimer-related model, with a methods inconsistency, and a negative report in a rat toxin model. That is a reason to keep model, outcome and paper in view, not to average the two into a general benefit claim.
What has not been shown in people or in Canadian authorization
No published clinical trial of dihexa itself was identified in the sources opened for this note. A ClinicalTrials.gov search for “dihexa” and for “PNB-0408” on 21 November 2026 returned no registered studies.
The U.S. Food and Drug Administration has published an assessment of dihexa acetate, the salt form named on its compounding pages. Dihexa acetate appears on the FDA list of bulk drug substances nominated for the 503A or 503B bulks lists and later withdrawn by the nominators. The agency's still-published wording is that it “has not identified any human exposure data on drug products containing dihexa acetate administered via any route of administration” and that it “lacks important information regarding any safety issues raised by dihexa acetate, including whether it would cause harm if administered to humans.” That statement concerns compounded drug products, not a research-use catalogue, but it is the clearest official wording found on human exposure data for this substance.
In Canada, a Health Canada Drug Product Database search on 21 November 2026 for the ingredient name “dihexa” and for “PNB-0408” returned no drug records. That is not a legal opinion; it only records that those ingredient searches did not return an authorized human drug under those names. BlueNex Labs materials are not medicines, are not authorized by Health Canada, and are not for human or animal use. See Are research peptides legal in Canada?.
Neighbouring catalogue peptides are not substitutes
Dihexa sits in the cognitive and neuroscience catalogue beside other research materials. They are not the same molecule, and they do not share a documented receptor class in the papers cited here.
Semax 10 mg and Selank are ACTH-fragment and tuftsin-related peptides, with notes on Semax, Selank and a Semax versus Selank comparison.
PE-22-28 10 mg is a separate sequence; see What is PE-22-28?.
Oxytocin 5 mg is a cyclic nonapeptide; see Oxytocin peptide in Canada.
DSIP belongs to a different sleep-architecture literature set.
McCoy and colleagues described dihexa as blood-brain-barrier permeant in their rat tracer experiment. That claim sits in the 2013 paper that now carries a Notice of Concern, so it should not be copied onto other vials. See peptides and the blood-brain barrier.
What to check on a Dihexa lot
As of the product page opened for this note, Dihexa 10 mg did not have a published Certificate of Analysis in the certificates library. Absence of a public file is not a substitute result. If a report is later posted, or supplied with a lot, the useful checks are the same as for other lyophilized research peptides:
The name on the report matches the vial: dihexa, PNB-0408, or N-hexanoic-Tyr-Ile-(6) aminohexanoic amide, not “angiotensin IV.”
Identity is supported by mass spectrometry or LC-MS, against an expected average mass near 504.7 Da, not a VYIHPF mass. See how peptide purity is measured.
Purity is a peak-area result for that lot. How to read a peptide Certificate of Analysis walks through the usual fields.
The fill size and lot identifier on the vial match the report. Publishing rules are on the documentation standards page.
Storage follows the lot file and ordinary lyophilized-peptide practice; see the Canadian storage guide and the lyophilized research peptides note.
None of these steps is a protocol for use.
Dihexa peptide in Canada: catalogue and fulfilment notes
BlueNex Labs is a Burnaby catalogue for lyophilized research materials, with Interac e-Transfer checkout and Canada Post Xpresspost shipping inside Canada only. Size, stock and current terms stay on the Dihexa 10 mg product page; this article is not a storefront and does not list prices. Other guides live on the research hub.
The listing is research use only. It is not a medicine, food, cosmetic or natural health product, is not authorized by Health Canada, and is not for human or animal use.
FAQ
What is Dihexa peptide?
Dihexa (PNB-0408) is a chemically modified angiotensin IV analogue named N-hexanoic-Tyr-Ile-(6) aminohexanoic amide. PubChem lists C27H44N4O5 and an average molecular weight of 504.7 g/mol for CID 129010512. It is supplied here only for laboratory research, not as a medicine.
Is Dihexa the same as angiotensin IV?
No. Angiotensin IV is the hexapeptide VYIHPF. Dihexa keeps only tyrosine and isoleucine from that sequence and uses non-standard end groups. The names should not be used interchangeably, and a mass check should use the expected mass for dihexa, not for angiotensin IV.
Has Dihexa been studied in people?
No published clinical trial of dihexa itself was identified for this note, and a ClinicalTrials.gov search for “dihexa” and “PNB-0408” on 21 November 2026 returned no registered studies. The FDA has stated that it has not identified human exposure data for dihexa acetate by any route, and that it lacks important safety information on harm if the substance were administered to humans.
Is there an authorized Dihexa medicine in Canada?
A Health Canada Drug Product Database search on 21 November 2026 for “dihexa” and “PNB-0408” returned no drug records. BlueNex Labs lists Dihexa 10 mg only for in-vitro laboratory research. It is not authorized by Health Canada and is not for human or animal use.
Why do some descriptions still mention HGF or c-Met?
A 2014 paper proposed that dihexa’s reported effects depended on the HGF/c-Met system. It was retracted in 2025 after a Washington State University investigation found falsified and/or fabricated data in specified figures and in a later erratum. The retracted article should not be used as evidence for that mechanism.
What should a laboratory check before assigning a Dihexa lot to an assay?
Match the vial name and lot to the Certificate of Analysis, when one exists. Confirm identity by mass spectrometry against the expected mass near 504.7 Da, and read the lot's own purity result. As of the product page opened for this note, a public COA had not yet been posted for this SKU.
Sources
1. McCoy AT, Benoist CC, Wright JW, Kawas LH, Bule-Ghogare JM, Zhu M, Appleyard SM, Wayman GA, Harding JW. Evaluation of metabolically stabilized angiotensin IV analogues as procognitive/antidementia agents. J Pharmacol Exp Ther. 2013;344(1):141-154. PMID 23055539. PMC3533412. doi:10.1124/jpet.112.199497. PubMed · PMC 2. Notice of Concern: McCoy AT, Benoist CC, Wright JW, Kawas LH, Bule-Ghogare JM, Zhu M, Appleyard SM, Wayman GA, and Harding JW (2013) Evaluation of Metabolically Stabilized Angiotensin IV Analogues as Procognitive/Antidementia Agents, J Pharmacol Exp Ther, 344: 141-154. J Pharmacol Exp Ther. 2021;378(3):313. PMID 34551989. doi:10.1124/jpet.112.199497concern. PubMed · Journal notice 3. Benoist CC, Kawas LH, Zhu M, Tyson KA, Stillmaker L, Appleyard SM, Wright JW, Wayman GA, Harding JW. The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-met system. J Pharmacol Exp Ther. 2014;351(2):390-402. PMID 25187433. doi:10.1124/jpet.114.218735. Retracted. PubMed 4. Retraction notice to “The Procognitive and Synaptogenic Effects of Angiotensin IV–Derived Peptides Are Dependent on Activation of the Hepatocyte Growth Factor/c-Met System” [*J Pharmacol Exp Ther* 351 (2014) 390-402]. J Pharmacol Exp Ther. 2025;392(4):103567. PMID 40312093. PMC13095468. doi:10.1016/j.jpet.2025.103567. PubMed · PMC 5. Sun X, Deng Y, Fu X, Wang S, Duan R, Zhang Y. AngIV-analogue Dihexa rescues cognitive impairment and recovers memory in the APP/PS1 mouse via the PI3K/AKT signalling pathway. Brain Sci. 2021;11(11):1487. PMID 34827486. PMC8615599. doi:10.3390/brainsci11111487. PubMed · PMC 6. Wells RG, Azzam AF, Hiller AL, Sardinia MF. Effects of an angiotensin IV analogue on 3-nitropropionic acid-induced Huntington's disease-like symptoms in rats. J Huntingtons Dis. 2024;13(1):55-66. PMID 38489193. doi:10.3233/JHD-231507. PubMed 7. PubChem. N-(1-Oxohexyl)-L-tyrosyl-N-(6-amino-6-oxohexyl)-L-isoleucinamide (Dihexa; PNB-0408), CID 129010512. National Center for Biotechnology Information. pubchem.ncbi.nlm.nih.gov/compound/129010512. Accessed 21 November 2026. 8. U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. Entry for dihexa acetate, under “Bulk drug substances nominated but withdrawn.” fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks. Accessed 21 November 2026.
Health Canada. Drug Product Database. Ingredient-name search for “dihexa” and “PNB-0408” returned no records. Accessed 21 November 2026 via the Drug Product Database API.
ClinicalTrials.gov. Searches for “dihexa” and “PNB-0408” returned no registered studies. Accessed 21 November 2026 via the ClinicalTrials.gov API v2.
References
- PMID 23055539
- PMID 34551989
- PMID 25187433
- PMID 40312093
- PMID 34827486
- PMID 38489193
Research use only. BlueNex Labs does not provide medical or veterinary advice. Confirm your institution’s policies before purchase. Lot-file rules for this note are on the documentation standards page. By Alice Kay.